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ABSTRACT  32 
Viruses must be able to resist host innate responses, especially the type I 33 
interferon (IFN) response. They do so by preventing induction or activity of IFN 34 
and/or by resisting the antiviral effectors it induces.  Poxviruses are no 35 
exception, with many mechanisms identified whereby mammalian poxviruses, 36 
notably vaccinia (VACV) but also cowpox and myxoma viruses, are able to evade 37 
host IFN responses. Similar mechanisms have not been described for avian 38 
poxviruses (avipoxviruses). Restricted for permissive replication to avian hosts, 39 
they have received less attention; moreover the avian host responses are less 40 
well characterised. We show that the prototypic avipoxvirus, fowlpox virus 41 
(FWPV) is highly resistant to the antiviral effects of avian IFN. A gain-of-function 42 
genetic screen identified fpv014 as contributing to increased resistance to 43 
exogenous recombinant chicken IFN-α (ChIFN1). Fpv014 is a member of the 44 
large family of poxvirus (especially avipoxvirus) genes that encode proteins 45 
containing N-terminal ankyrin repeats (ANKs) and C-terminal F-box-like motifs. 46 
By binding the Skp1/Cullin-1 complex, the F-box in such proteins appears to 47 
target ligands bound by the ANKs for ubiquitination. Mass spectrometry and 48 
immunoblotting demonstrated that tandem affinity-purified, tagged fpv014 was 49 
complexed with chicken cullin-1 and Skp-1.  Prior infection with an fpv014 50 
knockout mutant of FWPV still blocked transfected poly(I:C)-mediated induction 51 
of the IFNβ (ChIFN2) promoter as effectively as parental FWPV, but the mutant 52 
was more sensitive to exogenous ChIFN1. Therefore, unlike the related protein 53 
fpv012, fpv014 does not contribute to the FWPV block to induction of ChIFN2, 54 
but does confer resistance to an established antiviral state. 55 
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INTRODUCTION 56 
The major mammalian innate host response to virus infection is the type I 57 
interferon (IFN) system, consequently many viruses have evolved mechanisms 58 
to evade or subvert it (1, 2). The prototypic mammalian poxvirus, vaccinia virus 59 
(VACV), encodes a number of proteins that have been shown to modulate the IFN 60 
system in diverse ways (reviewed by Perdiguero et al. (3)). They include double-61 
stranded (ds) RNA-binding protein E3 (4), eIF-2α mimic K3 (5), soluble IFN 62 
receptor mimic B18 (6, 7), Stat phosphorylation inhibitor H1 (8) and NF-κB 63 
activation suppressor K1 (9). With the exception of H1, no type I IFN modulators 64 
have yet been identified for the avipoxviruses. 65 
 66 
The genomes of the avipoxviruses are larger than those of the mammalian 67 
poxviruses. Although the genomes of two avipoxviruses, Fowlpox virus (FWPV; 68 
type species of the Avipoxvirus genus) and Canarypox virus (CNPV), have been 69 
sequenced (10, 11), there are no obvious orthologs of the VACV IFN modulators 70 
(such as E3L, K3L and B18R), with the exception of an ortholog of H1 (12). The 71 
lack of E3L and K3L is a feature not unique to avipoxviruses - they are also 72 
absent from the now only remaining extant human poxvirus, molluscum 73 
contagiosum virus, which causes chronic infection (13). Avipoxviruses also lack 74 
members, several of which are immunomodulatory (14-20), of the family of 75 
proteins found in VACV that share a structural fold with host apoptosis-76 
controlling Bcl-2 (17). Avipoxviruses do encode potential orthologs of 77 
immunoregulators less frequently found in mammalian poxviruses, such as the 78 
IL-10 analogue encoded by CNPV ((11) and found in mammalian poxviruses 79 
other than VACV, e.g. Orf virus (21)) and TGF-β orthologs found initially in FWPV 80 
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(10) and CNPV (11)  then subsequently in deerpox virus (22). Ligand-binding 81 
studies have also identified a binding protein for chicken IFN-γ, distinct from 82 
IFN-γ-binding proteins encoded by mammalian poxviruses (23).  83 
 84 
We show here that FWPV is highly resistant to chicken type I IFN (ChIFN), 85 
considerably more so than the artificially chicken cell-adapted strain of VACV, 86 
modified virus Ankara (MVA) and that the resistance is due to FWPV encoded 87 
protein(s). We have used a broad-scale genetic screen to search for modulators, 88 
encoded by the FWPV genome, involved in subverting the IFN response. This 89 
‘gain-of-function’ screen involved construction of a library of chimeric MVA 90 
viruses, each carrying 4 or 8 kbp segments of the FWPV genome, which were 91 
then screened to identify a gene(s) conferring enhanced resistance to chicken 92 
type I IFN. The screen identified a member of a large poxvirus gene family that is 93 
particularly extensive in avipoxviruses, members of which had not been 94 
previously associated with subverting the IFN response.  95 
 96 
MATERIALS AND METHODS 97 
 98 
Cells and viruses 99 
Primary chicken embryo fibroblasts (CEF), derived from specific pathogen free 100 
(SPF)-quality 10-day old embryos, and provided by the Institute for Animal 101 
Health (Compton, Berkshire, U.K.) were grown in 199 medium supplemented 102 
with 10% tryptone phosphate broth (TPB), 10% newborn bovine serum, 103 
nystatin and penicillin/streptomycin.  Immortalised chicken fibroblast DF-1 cells 104 
(24) sourced from the American Tissue Culture Collection (ATCC), were 105 
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maintained in DMEM supplemented with 10% Foetal Bovine Serum (Autogen 106 
Bioclear) and penicillin/streptomycin. 107 
 108 
Throughout this study we have used the previously described, attenuated FWPV 109 
strain FP9, as well as its pathogenic European progenitor, HP-1 (25). VACV VTN, 110 
a Western Reserve (WR) recombinant virus expressing the porcine transmissible 111 
gastroenteritis virus (TGEV) nucleoprotein in the thymidine kinase (TK) locus 112 
(26), was a gift from P. Britton (Institute for Animal Health, Compton U.K.). 113 
Parental VACV MVA (II/85), from laboratory stocks, was originally provided by 114 
Anton Mayr (Ludwig-Maximilians University, Munich, Germany). Recombinant 115 
VACV MVA-LZ, derived by insertion of the empty β-galactosidase selection 116 
plasmid, pSC11, at the TK locus, and known originally as MVA-SC11 (27), was 117 
provided by S. Gilbert, University of Oxford, U.K. The avirulent A7(74) strain of 118 
Semliki Forest virus (SFV) was donated by J. Fazakerley (University of 119 
Edinburgh, U.K.). 120 
 121 
Plasmids  122 
The ChIFN2 promoter reporter (pChIFN2lucter (28)) and the constitutive β-123 
galactosidase reporter plasmid (pJATlacZ (29)) have been previously described, 124 
as has pEFPlink2, which uses the elongation factor Iα promoter to direct high 125 
levels of expression of cloned cDNAs, as originally described by Marais et al. (30). 126 
 127 
Transfection of cells with poly(I:C) and assay of luciferase reporters 128 
Chicken DF-1 cells in 12-well plates were transfected with the chicken IFN-2 129 
promoter reporter (pChIFN2lucter) and the constitutive reporter plasmid 130 
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pJATlacZ. Sometimes they were additionally transfected with mammalian 131 
expression vector pEFPlink2 driving the overexpression of viral proteins, or 132 
empty as a control vector. Following recovery for 24 hours cells were either left 133 
uninfected or infected with either wild type fowlpox virus (FP9) or knockout 134 
virus at an MOI of 10. Following infection for 4 hours, cells, when appropriate, 135 
were transfected with poly(I:C) (10µg/ml) using Polyfect (Qiagen) or 136 
Lipofectamine (Invitrogen), as described by Childs et al. (28), and incubated for 137 
16 hours. Luciferase assays were carried out and data were normalised using β-138 
galactosidase measurements. 139 
 140 
Chicken IFN-α 141 
Preliminary studies were undertaken using recombinant chicken IFN-α (ChIFN1, 142 
(31), P. Staeheli, University of Freiburg, Germany). Subsequently the ChIFN1 143 
gene was amplified from CEF DNA by PCR and cloned it into pEFPlink2 using 144 
NcoI and XbaI sites. This plasmid was transfected into 293 cells (9cm plate); the 145 
supernatant, collected after 48 h incubation, was centrifuged to remove cell 146 
debris and was titrated by 50% plaque reduction assay (32) using SFV A7(74) on 147 
CEF. 148 
 149 
Construction of FWPV-chimeric MVA 150 
The approach adopted, after considerable optimisation of the individual steps, 151 
involved using Splice-Overlap-Extension (SOE) PCR to assemble 10 kbp linear 152 
recombination templates from four constituent parts: (i) 8 (or 4 kbp) PCR 153 
fragments of the FWPV genome (amplified using high fidelity Taq polymerase), 154 
flanked to the left by  (ii) MVA sequences (20406 to 20894), to the proximal right 155 
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by (iii) a VACV p7.5 promoter upstream of the E. coli gpt gene and to the distal 156 
right by (iv) MVA sequences (20916 to 21472). Parts (iii) and (iv) were pre-157 
assembled by SOE PCR before assembly of the complete linear recombination 158 
template from the resulting three components. The templates were purified by 159 
agarose gel electrophoresis, where crystal violet was used as the stain, rather 160 
than ethidium bromide, to avoid UV damage to the long templates. 161 
 162 
The assembled FWPV genomic DNA selection cassettes were transfected into DF-163 
1 cells previously infected with an MVA recombinant, MVA-LZ (which carries the 164 
E. coli lacZ gene inserted into the MVA thymidine kinase locus under control of 165 
the VACV p11 promoter to facilitate plaque identification by staining for β-166 
galactosidase). Recovered viruses were bulk passaged three times in CEF under 167 
mycophenolic acid selection (in the presence of xanthine and hypoxanthine) for 168 
the gpt gene. Viral genomic DNA was then extracted and analysed by PCR to 169 
confirm recombination of the FWPV genomic insert and loss of parental virus. 170 
Internal primers for the overlapping FWPV fragments were used for 171 
recombinant-specific PCR, together with MVA flanking primers to detect the 172 
presence of residual parental virus (the larger recombinant-specific product 173 
being product out-competed by any smaller parental-specific product). If 174 
parental MVA-LZ virus remained at this stage, the chimeras were subjected to 175 
plaque purification. Some chimeras made with 8 kbp FWPV inserts returned PCR 176 
products shorter than expected, or no products at all. Such viruses were not 177 
further characterised but were labelled as “unstable”. 178 
 179 
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Single FWPV gene recombinant MVA, each carrying one gene from the FIR1 180 
locus, were constructed by SOE PCR using single gene primers (012 forward: 181 
CATAATACAAGGCACTATGTCCTTATTTTCTTCCGAACCTACC, 182 
012 reverse: GTATTCTGGAGGCTGCATCCTTATTAAACCCGGAAATGTG 183 
013 forward: CATAATACAAGGCACTATGTCCAACGCATTTTTACCGTATTG 184 
013 reverse: GTATTCTGGAGGCTGCATCCTGAAGAAGATCTCCCTTATTG 185 
014 forward: CATAATACAAGGCACTATGTCCCGTAACTCTTGTTTTCATTTTTC 186 
and 014 reverse: GTATTCTGGAGGCTGCATCCACATCAGCAGTTTTATTTTTG). 187 
 188 
Construction of knock-out and knock-in recombinant FWPV 189 
To construct knock-out FWPV, SOE PCR (using high fidelity Taq polymerase) was 190 
used to assemble linear recombination templates from three constituent parts: 191 
approximately 350 bp PCR fragments of the FWPV genome from either side, (i) 192 
and (ii), of the centre of the target gene, disrupted in the middle (iii) by a VACV 193 
p7.5 promoter upstream of the E. coli gpt gene. The templates were purified by 194 
agarose gel electrophoresis and transfected into CEF previously infected with 195 
FWPV FP9. Recovered viruses were bulk passaged three times in CEF under 196 
mycophenolic acid selection (in the presence of xanthine and hypoxanthine) for 197 
the gpt gene then plaque purified. Viral genomic DNA was then extracted and 198 
analysed by PCR to confirm disruption of the target gene and loss of parental 199 
virus. Primers used were 5’-CGAACGTAGATTCCTACACTC and 5’-200 
TGATAAATTACAACTATTAAC for fpv012, 5’-ATTATGAAAACCACGAAAGTC and 5’-201 
AACGTCTATCAGAACCTAAAG for fpv014. 202 
 203 
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To construct knock-in viruses expressing full length or C-terminally deleted 204 
tandem affinity purified (TAP)-tagged fpv014, transient dominant plasmids 205 
pUC13-FL014TAP and pUC13-CtDel014TAP were constructed in two steps. 206 
Firstly the 400bp 3' flanking sequence of fpv014 was amplified by PCR and 207 
cloned into the poxvirus transient dominant TAP vector pUC13TAP (from Prof. G. 208 
Smith), such that the 3' flanking sequence was downstream of the TAP tag, 209 
generating the intermediate plasmid pUC13TAP014-3’. Subsequently FL or CtDel 210 
fpv014 (minus the stop codon) and 400 bp of upstream sequence were amplified 211 
by PCR and cloned into pUC13TAP014-3’ so that the fpv014 ORF was fused in 212 
frame with the TAP tag. Constructs were sequenced to ensure no errors had been 213 
introduced. 214 
 215 
Recombinant TAP-tagged fpv014 viruses were generated by transfection of the 216 
constructs into CEFs infected with a mutant FWPV FP9 previously deleted for the 217 
parental fpv014 by the transient dominant selection method (33) The knock-in 218 
mutants were then isolated by the transient dominant selection method under 219 
mycophenolic acid selection (in the presence of xanthine and hypoxanthine) for 220 
the gpt gene. Recombinant viruses were checked by PCR for the presence of the 221 
FL or CtDel fpv014 genes (data not shown). 222 
 223 
Plaque reduction assays 224 
CEF were pretreated for 16 to 18 h with ChIFN1 diluted in growth medium with 225 
2% NBBS. The medium was aspirated and cells were infected with about 50 226 
plaque-forming units per well. After 90 min incubation, excess virus was 227 
aspirated and solid overlay containing 1 % agarose was added to cells. Plaques 228 
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were fixed with 10% formaldehyde and stained with 20 % crystal violet in 20 % 229 
ethanol, 30 h (SFV), 3 d (VACV) or 4 d (MVA and FWPV) post-infection, counted 230 
and expressed as a percentage of mean (n=3) plaques formed in mock-treated 231 
wells. LacZ positive viruses were visualized by addition of solid overlay 232 
containing X-gal (0.4 mg ml-1). 233 
 234 
RNA extraction and processing of samples 235 
RNA was extracted from cells using an RNeasy kit (Qiagen) according to the 236 
manufacturer’s instructions. On-column DNA digestion was performed using 237 
RNase-free DNase (Qiagen) to remove contaminating genomic DNA. RNA 238 
samples were quantified using a Nanodrop Spectrophotometer (Thermo 239 
Scientific) and checked for quality using a 2100 Bioanalyzer (Agilent 240 
Technologies). All RNA samples had an RNA integrity number (RIN) ≥ 9.6.  241 
 242 
Reverse transcription (RT) PCR and quantitative real-time RT PCR 243 
qRT-PCR was performed using MESA GREEN qPCR MasterMix Plus for SYBR® 244 
Assay I dTTP (Eurogentec) according to the manufacturer’s instructions. A final 245 
volume of 10μl per reaction was used, with 1μl cDNA diluted 1:10 in nuclease-246 
free H2O as a template. Primers were used at a final concentration of 300nM. 247 
qPCR was performed on an ABI-7900HT Fast Real-Time PCR System (Applied 248 
Biosystems) using the following programme: 95°C for 5 minutes; 40 cycles of 249 
95°C for 15 seconds, 57°C for 20 seconds, 72°C for 20 seconds; 95°C for 15 250 
seconds; and 60°C for 15 seconds.  251 
 252 
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The qRT-PCR primer pairs (GGCACTGTCAAGGCTGAGAA and 253 
TGCATCTGCCCATTTGATGT for ChGAPDH; TGCTCTCCAGGGGTGCGTTACCand 254 
TAGCGCCGTGTTCCAACAGCG for fpv014; GTGTTCACGCCAAAGTAG and 255 
AGTAGGTTCTTCGTCAGATG for fpv100; ACCTCAAACAACCTCATC and 256 
GTTAATACTTGTGACTGCTG for fpv168) were validated by generating standard 257 
curves using PCR products corresponding to each gene. A 10-fold dilution series 258 
was made for each PCR product and 1 µl was used with the MESA green qPCR 259 
mastermix. Ct values were analysed using SDS2.3 (Applied Biosystems). The 260 
slopes of the standard curves were used to identify the amplification efficiencies 261 
(E) of the qRT-PCR primer pairs, using the equation E = 10(-1/slope) -1. Only 262 
qRT-PCR primer pairs with efficiencies of 90-110% were used further. The linear 263 
correlation coefficient (R2) was used to assess the linearity of the standard 264 
curve. Standard curves with an R2 value of >0.985 were used. 265 
 266 
Data were analysed using SDS 2.3 and RQ Manager 1.2 software (Applied 267 
Biosystems). All target gene expression levels were calculated relative to 268 
expression levels of the reference gene, glyceraldehyde 3-phosphate 269 
dehydrogenase (GAPDH), which were shown to remain constant over 24 h in 270 
uninfected and FP9-infected cells, and the target gene expression level in control 271 
CEF, using the comparative CT method (also referred to as the 2–ΔΔCT method). 272 
 273 
Tandem affinity purification 274 
FPV014 was cloned into a TAP-tagging vector (kind gift of B. Ferguson) 275 
comprising a pcDNA4-TO (Invitrogen) backbone and a C-terminal SF-TAP tag 276 
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(34).     CTAP-tagged 014 was transfected into DF1-TR cells and resulting 277 
transformants selected using BlasticidinS and Zeocin, generating a CTAP014 278 
inducible cell line. Twenty T175 flasks of CTAP014 were grown up and 279 
expression of 014 was induced in ten of them by the addition of doxycycline. 280 
Twenty-four hours following induction cell lysates were made and sequential 281 
immunoprecipitations carried out, firstly with Streptactin beads (IBA) and 282 
secondly with Flag beads (Sigma). Final elutions were concentrated using a 283 
3KMWCO micron ultrafiltration device (Millipore) and samples were run on an 284 
SDS polyacrylamide gel and stained using coomassie blue. Protein bands that 285 
appeared in the induced and not the uninduced sample were excised and 286 
submitted for tandem mass spectrometry at the CISBIO mass spectrometry core 287 
facility (Imperial College London, managed by Dr Paul Hitchen). 288 
 289 
 290 
RESULTS 291 
 292 
Fowlpox virus is resistant to the antiviral effects of chicken type I IFN.  293 
The sensitivity of FWPV FP9 replication to exogenous ChIFN was measured by 294 
plaque reduction on primary chicken embryo fibroblasts (CEF) in the presence of 295 
recombinant ChIFN1. In our preliminary studies in CEF, the IC50 for the control 296 
virus, Semliki Forest virus (SFV) A7(74), was by definition, 1 U ml-1, while that 297 
for VACV WR (VTN) was 176 U ml-1 (Fig. 1). VACV MVA, which was derived by 298 
extensive CEF passages (more than 500), during which it underwent 299 
considerable deletion of genomic sequences relative to its parental strain, 300 
chorioallantois Vaccinia virus Ankara (35-37), had an IC50 of only 7 U ml-1. FP9, 301 
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however, proved far more resistant (Fig. 1), such that the number of plaques was 302 
reduced only by 36 % at the highest concentration of ChIFN used (1563 U ml-1). 303 
The ChIFN used in this preliminary study caused some cytotoxicity at high 304 
concentrations (Fig. 1A), so the IC50 for FP9 could initially only be estimated 305 
upon extrapolation by non-linear regression, yielding a tentative figure of 2570 U 306 
ml-1.  307 
 308 
Identification of FWPV chimeric MVA with enhanced resistance to ChIFN1.  309 
The observation that MVA is almost 400-fold more sensitive to the antiviral 310 
effects of ChIFN1 than FP9 (Fig. 1) presented the possibility of a gain-of-function 311 
genetic screen of the FWPV genome, using MVA as a recipient, to attempt to 312 
identify gene(s) involved in the enhanced resistance of FP9 to ChIFN1.   313 
 314 
A panel of 63 MVA-FWPV chimeras were generated, as described in Materials 315 
and Methods, together spanning much of the FP9 genome in 4 or 8 kbp inserts 316 
(Fig. 2a), inserted close to deletion II of MVA (35), in an intergenic region mid 317 
way between the end of MVA023L and the start of MVA021L. The design strategy 318 
foresaw a tiling path of 8 kbp fragments overlapping by 4 kbp but not all 319 
chimeras were isolated and some (which we define as “unstable”) proved to have 320 
smaller inserts than expected, as determined by PCR analysis, possibly due to 321 
competition between equivalent VACV and FWPV proteins. The library was 322 
evaluated to cover 85% of the FWPV ORFs (with 64% of the ORFs in one or more 323 
viruses). 324 
 325 
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Although poxvirus promoters from VACV have been shown to function in cells 326 
infected by FWPV, and vice versa, the ability of an MVA chimera to express a 327 
FWPV protein from its cognate promoter in the inserted FWPV genomic DNA 328 
was demonstrated by western blotting, with monoclonal antibody (MAb) DE9, 329 
cell-free extract from cells infected with chimeras. MAb DE9 recognises the 63 330 
kDa FWPV equivalent of VACV p4c, encoded by fpv191 (38), located in fragment 331 
50 of the chimeric library. Three independent chimeras (MVA-f50a, b and c) 332 
were isolated following separate transfections with fragment 50. Chimeras MVA-333 
f50a and MVA-f50c but not “unstable” chimera MVA-f50b nor control chimera 334 
MVA-fC2b showed strong expression of fpv191 (Fig. 2b).  335 
 336 
A total of 28 of the chimeras (none of which were classified as “unstable”) were 337 
screened, by plaque reduction assay, for enhanced resistance to low titres of 338 
ChIFN1 (10 to 16 U ml-1). Data from the screening of 18 such chimeras are shown 339 
in Fig. 3.  Chimera MVA-f3La was readily identified as having significantly higher 340 
resistance than the control and other chimeras, whether screened as third bulk-341 
passage (Fig. 3a) or plaque-purified  (Fig. 3b) virus. Only one other chimera, 342 
MVA-f6b, demonstrated resistance to ChIFN1 significantly higher than the 343 
control (but less than that of MVA-f3La; data not shown). It carried an 8kbp locus 344 
that we named Fowlpox virus IFN Regulator 2 (FIR2), comprising position 345 
23791 to 32167 of the FWPV FP9 sequence accession AJ581527 (25) and 346 
spanning ORFs fpv022 to fpv026, inclusive, all of which are transcribed from right 347 
to left. Chimera MVA-f3La carried only a 4 kbp segment of the FWPV genome 348 
(position 11900 to 16043 of the FP9 sequence), spanning three ORFs (fpv012 to 349 
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fpv014, inclusive, all of which are transcribed from right to left). We named this 350 
genomic locus FIR1. 351 
 352 
Identification of an FWPV gene contributing to virus resistance to ChIFN1.  353 
Firstly, expression of FWPV genes fpv012 and fpv014 in CEF infected with MVA-354 
f3La but not with control MVA-fC2a was demonstrated by qRT-PCR; in fact both 355 
FWPV genes were expressed at higher levels from the chimera than from donor 356 
FP9 (Fig. 4). Then recombinant MVA, each carrying just a single gene from the 357 
FIR1 locus, were constructed by SOE PCR. Expression of fpv014, as determined 358 
by qRT-PCR, was lower in MVA-F.014 (13 & 60 fold, relative to FP9, at 8 & 16 hpi, 359 
respectively) than in MVA-f3La (26 & 81 fold), while fpv012 expression was 360 
higher in MVA-F.012 (15 & 43 fold) than in MVA-f3La (5 & 20 fold) (Fig. 4). 361 
 362 
The single gene recombinant MVA were similarly screened for enhanced 363 
resistance to ChIFN1 by plaque reduction assay. Preliminary experiments (for 364 
example Fig. 5a) showed that fpv013 did not contribute to enhanced ChIFN1 365 
resistance. Subsequent experiments demonstrated that plaque formation by 366 
MVA-f3La, under different concentrations of ChIFN1, was significantly higher 367 
than that by the control MVA-fC2a and the recombinant (MVA-F.012) expressing 368 
only fpv012 but not the recombinant (MVA-F.014) expressing only fpv014 (Fig. 369 
5b and c). MVA-F.014 consistently plaqued at considerably higher efficiency than 370 
MVA-fC2a and MVA-F.012 but the results did not reach statistical significance. 371 
The IC50 of ChIFN1 for each of the viruses was therefore derived in a further 372 
experiment. The IC50 for MVA-f3La (68 U ml-1) was significantly higher than 373 
those for MVA-fC2a (25 U ml-1) and MVA-F.012 (18 U ml-1). Although that for 374 
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MVA-F.014 (41 U ml-1) was not significantly higher than that for MVA-fC2a, it 375 
was significantly higher than that for MVA-F.012 (Fig. 5d). It is therefore only 376 
fpv014 that consistently shows a contribution towards the resistance to ChIFN1 377 
observed in MVA-f3La. 378 
 379 
Expression of fpv014 by FWPV. 380 
Analysis of fpv014 mRNA expression by qRT-PCR revealed that its levels and 381 
kinetics in CEF infected with parental FWPV FP9 are comparable to those of 382 
fpv100 (Fig. 6a), with expression clearly detectable at 2h (in contrast to late gene 383 
fpv168) and increasing to 8h in an AraC-sensitive manner (though in contrast to 384 
the highly expressed late gene fpv168, low level expression is still detectable in 385 
the presence of AraC). Gene fpv100 is an ortholog of VACV E4L (VACWR060), 386 
which encodes RNA polymerase subunit RPO30 and shows group E1.1 387 
expression kinetics (39).  388 
 389 
Antibodies for fpv014 are still unavailable but a TAP-tagged version of the gene 390 
was inserted back into the native locus under control of the cognate promoter 391 
and its expression was demonstrated by western blotting of lysates with anti-392 
FLAG antibodies (Fig. 6b). 393 
 394 
Characterization of an fpv014 knockout mutant of FWPV.  395 
In an accompanying paper (Laidlaw et al.; JVI02736-12), a library of single gene 396 
knockout FWPV was screened to identify genes involved in blocking the 397 
induction of chicken IFN-β (ChIFN2 (31)). Another gene in the FIR1 locus, 398 
fpv012, was shown to contribute towards blocking the induction of ChIFN2 399 
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mediated by transfected dsRNA analog, poly(I:C). Conversely, even though 400 
fpv014 contributed to the enhanced resistance to the established antiviral state 401 
observed for chimeric MVA-f3La carrying the FIR1 locus, it did not contribute 402 
towards blocking the transfected poly(I:C)-mediated induction of ChIFN2 in 403 
immortalized chicken fibroblast cell line DF-1 cells (Fig. 7A). Nor did fpv014, 404 
unlike fpv012, inhibit the transfected poly(I:C)-mediated induction of ChIFN2 405 
when expressed ectopically from a eukaryotic promoter (data not shown). As 406 
fpv014 confered enhanced resistance to MVA chimeras, then its loss from FWPV 407 
FP9 should result in decreased resistance of the knockout virus. The IC50 of 408 
ChIFN1 for the fpv014-knockout virus was therefore derived in comparison with 409 
that for parental FP9 (Fig. 7B) using ChIFN1 that did not cause the cytotoxicity 410 
seen in the preliminary study (Fig. 1A), so that the IC50 did not have to be 411 
calculated by extrapolation. At 2008 U ml-1, the IC50 for the fpv014-knockout 412 
virus proved to be significantly different to that for parental FP9 (5564 U ml-1). 413 
 414 
IFN modulator fpv014 is a member of the ANK/PRANC poxvirus gene 415 
family.  416 
The inhibitor of IFN responses identified by this study, fpv014, is encoded by a 417 
member of the largest poxvirus gene family, These proteins have an N-terminal 418 
domain (INTERPRO IPR020683) containing multiple copies (7 in the case of 419 
fpv014) of the ankyrin repeat (ANK; INTERPRO IPR002110). Most of them, 420 
including fpv014 (Fig. 8a), have been described by Mercer and colleagues (40) as 421 
ANK/PRANC proteins, with multiple ANKs and a C-terminal F-box like motif in a 422 
PRANC domain (Pox protein Repeats of ANkyrin – C terminal; INTERPRO 423 
IPR018272).  424 
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 425 
fpv014 interacts with proteins of the SCF complex  426 
To identify ligands for fpv014, its gene was cloned into a C-terminal TAP tagging 427 
vector placing its expression under the control of the tetracycline operator 428 
element. Stable transformants containing the TAP-tagged constructs were 429 
established in a derivative (S. Laidlaw, unpublished) of the immortalised DF-1 430 
chicken fibroblast cell line expressing a tetracycline-dependent transactivator. 431 
Tandem affinity purification was then conducted on lysates from non-induced 432 
and doxycycline-induced cells. Tandem mass spectrometry of co-precipitated 433 
bands purified by SDS-PAGE demonstrated that fpv014 is complexed with 434 
chicken Cullin-1 (Fig. 8b). In this regard, fpv014 behaves like several other 435 
members of the ANK/PRANC family from poxviruses that infect mammals, 436 
namely cowpox virus, ectromelia virus, myxoma virus, Orf virus and vaccinia 437 
MVA (41-46), indicating that fpv014 also functions via the SCF ubiquitin ligase 438 
complex. The PRANC proteins interact indirectly with cullin-1 via Skp1 as an 439 
adaptor. Skp1 was not identified in any of the bands excised for mass 440 
spectrometry so the affinity-purified TAP-tagged fpv014 eluate (and fpv014 non-441 
expressing control cell lysate) were analysed by western blotting. Non-reducing 442 
conditions were used for SDS-PAGE, as the samples had been prepared for 443 
compatibility with subsequent mass spectrometry. Under these non-reducing 444 
conditions, TAP-tagged fpv014, detected in the purified eluates from expressing 445 
cell lines (but not in control lysates) by antibody recognising the FLAG epitope in 446 
the TAP tag, migrated as two pairs of bands (the upper of each pair being 447 
predominant; Fig. 8c). The lower pair migrated just above the 50 kDa marker, 448 
consistent with the expected size (53 kDa) of TAP-tagged fpv014. The upper pair 449 
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migrated just below the 75 kDa marker, consistent with a 72 kDa complex 450 
between TAP-tagged fpv014 and Skp1 (19 kDa). Immunoblotting detected Skp1 451 
in the control lysates, at the expected size of 19 kDa (Fig. 8c). In the purified 452 
eluates from TAP-fpv014 expressing cells, some Skp1 was evident at 19 kDa, but 453 
most of it co-migrated (at 72 kDa) with the slower migrating pair of TAP-tagged 454 
fpv014 bands (Fig. 8c). Immunoblotting also detected cullin-1 in the control 455 
lysates, at the expected size of 90 kDa (Fig. 8c). The cullin-1 in the purified 456 
eluates from TAP-fpv014 expressing cells, however, migrated slightly slower 457 
than in the control lysates (consistent with the 98 kDa ubiquitinated form of 458 
Cullin-1 observed to interact with the myxoma virus PRANC protein MNF (41)). 459 
Even though this cullin-1 co-purified with TAP-tagged fpv014 in the eluate. it was 460 
not observed in a complex with TAP-tagged fpv014 (predicted 143 kDa, or 162 461 
kDA with the addition of Skp1) on the immunoblot, whether due to SDS-462 
sensitivity of the complex or to the inability of the antibody to bind complexed 463 
cullin-1. We have been unable to source an antibody for another member of the 464 
complex, RBX/Roc1, that functions appropriately with chicken cell extracts. 465 
 466 
DISCUSSION 467 
Vaccinia virus (VACV), the type species of the orthopoxviruses and the most 468 
extensively studied poxvirus, has been shown to encode a considerable number 469 
of proteins that, though non-essential for replication in vitro, contribute to 470 
virulence and/or the ability of the virus to replicate in vivo. Such proteins 471 
generally modulate the innate immune system of the host, and are generically 472 
known as immunomodulators. Initially, many of these proteins were identified 473 
by their sequence similarity with host immune effectors, probably derived by 474 
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lateral gene transfer. Examples include soluble binding proteins for IFNs and 475 
interleukins (6, 7, 47, 48). Similar proteins are encoded by members of other 476 
genera of mammalian poxviruses (49, 50). Later, such proteins were identified 477 
by functional or ligand-binding studies (51, 52) and, more recently, by structural 478 
(but not primary sequence) similarity to host effectors (14, 16). 479 
 480 
Such approaches have not proved particularly successful for identifying 481 
immunomodulators encoded by avipoxviruses (10, 12, 23). Despite the apparent 482 
absence from FWPV of IFN modulators equivalent to those found in VACV, and of 483 
other candidate IFN modulators readily identified by their sequence homology 484 
with known host components or targets of the IFN system, our data show that 485 
FWPV effectively subverts the antiviral effects of avian IFN, even in an 486 
established antiviral state. Indeed, FWPV can even rescue co-infecting IFN-487 
sensitive viruses such as SFV (unpublished data), indicating that at least some of 488 
the mechanisms can operate in trans. 489 
 490 
A two-stage genetic screening strategy was employed in an attempt to identify 491 
FWPV genes involved in resisting the antiviral effectors of the type I IFN system. 492 
The first-stage screen identified a locus comprising just 3 genes (fpv012, fpv013 493 
and fpv014) and the second stage identified fpv014. The first-stage chimera, 494 
MVA-f3La, carrying 3 genes, appeared more resistant than the one carrying the 495 
only gene that contributed to ChIFN1 resistance (fpv014) but qRT-PCR analysis 496 
later revealed that fpv014 expression levels were lower in the single gene 497 
chimera than in the 3 gene chimera, suggesting that the levels of fpv14 498 
expression account for the difference in the levels of resistance observed. It is 499 
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notable that the fold change in IC50 of the MVA chimeras upon introduction of 500 
fpv014 is comparable in scale (but opposite in direction) to the fold change in 501 
FWPV FP9 upon deletion of fpv014, reinforcing the view that the MVA screen 502 
offers a valid representation of the role of FWPV IFN modulators in their normal 503 
context.  504 
 505 
Both fpv014 and fpv012 are members of an extensive gene family encoding ANK 506 
proteins, which are found throughout the evolutionary tree in more than 40,000 507 
proteins from viruses and bacteria to higher plants and animals. They mediate 508 
protein-protein interactions and so are found in proteins with all manner of 509 
functions, roles and localisation (53). With the curious exception of MOCV, 510 
mammalian poxviruses all encode ANK proteins, the actual number varying from 511 
4 to 31 members (54, 55) but the higher numbers often represent partial 512 
pseudogenes and the actual number of orthologous groups in mammalian 513 
poxviruses is estimated as being from 5 in parapoxviruses to 15 in 514 
orthopoxviruses (55).  The family appears to have expanded considerably in the 515 
avipoxviruses, with 31 members in a pathogenic FWPV (10) and 51 in a 516 
pathogenic 1948 isolate of CNPV (11). The number of orthologous groups cannot 517 
yet be estimated for the avipoxviruses, because so far only the genome 518 
sequences of FWPV and CNPV have been published, but the known ANK genes 519 
represent 11% and 15%, respectively, of the total gene complement of these 520 
viruses. About 70% of them have F-boxes suggesting they are likely to be intact, 521 
in contrast with only 36% in the only mammalian poxvirus that encodes more 522 
than 20 ANKs, horsepox virus (55, 56). Extensive passage (more than 430 times) 523 
of pathogenic FWPV HP-1 through CEF culture by Anton Mayr, with concomitant 524 
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attenuation (57), led to the loss or disruption of 12 FWPV ANK genes in FP9 but 525 
the only change to fpv014 resulted in a conservative Asp to Glu substitution at 526 
residue 225 of fpv014 (25). Given the high level of resistance of FP9 to ChIFN1, 527 
we have no reason to expect that HP-1 fpv014 should be any more effective than 528 
that of FP9. Apart from FWPV, the only other member of the Avipoxvirus genus 529 
for which the genome sequence has been published is CNPV, which is 530 
considerably diverged from FWPV, displays significant differences in gene 531 
complement (10, 11) and is found in a different major clade of the genus (58). 532 
Comparisons between ANK proteins can be problematic but Sonnberg et al. (55) 533 
reported the most likely CNPV ortholog of fpv014 to be cnpv019 (48% amino acid 534 
identity). These orthologs are not in syntenic positions; and we have not yet 535 
assessed whether cnpv019 can contribute to enhanced ChIFN1 resistance in the 536 
MVA model. 537 
 538 
The combination of N-terminal ANK and C-terminal F-box/PRANC domains 539 
found in fpv014 is essentially restricted to poxviruses, though ANK/PRANC 540 
genes have now been found in Nasonia parasitic wasps, apparently transferred 541 
to them horizontally via endosymbiotic Wolbachia rickettsial bacteria (59). The 542 
PRANC domains of a number of mammalian poxvirus ANK proteins have been 543 
shown to mediate interaction with core components of the ubiquitin ligase 544 
complex (41, 42, 45, 46, 60)  It was postulated (40, 43) that such interactions 545 
would target for ubiquitination ligands captured by the N-terminal ANK 546 
domains. However, the identities of cellular ligands captured by the ANK domain 547 
have been established for only an extremely small minority of poxvirus ANK 548 
proteins (61). Thus Akt appears to be the target for myxoma virus MT-5 (62), 549 
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while NF-κB is bound by variola virus G1R (63) and its cowpox virus (CPXV) 550 
ortholog CPXV006 (64) as well as by CPXV CP77/CPXV025 (42).   551 
 552 
Despite considerable effort, we have been unable to identify a cellular ligand for 553 
the N-terminal ANK domain of fpv014. Although it was not our main goal, we 554 
were able to demonstrate tandem affinity co-purification of chicken cullin-1 (by 555 
mass spectrometry and immunoblotting) and chicken Skp1 (by immunoblotting 556 
only) with TAP-tagged fpv014. This indicated that fpv014 interacts with the 557 
avian ubiquitin ligase complex (presumably via the F-box) in the same way that 558 
PRANC proteins of mammalian poxviruses have been shown to interact with the 559 
mammalian complexes. The immunoblotting was performed after non-reducing 560 
SDS-PAGE, not to look for complexes but for compatibility with subsequent mass 561 
spectrometry. The observation that most of the co-purified Skp1 co-migrated 562 
with a substantial proportion of the TAP-tagged fpv014 was, therefore, 563 
somewhat serendipitous. However, it suggests that fpv014 and chicken Skp1 can 564 
form an SDS-stable complex. Unfortunately, we were not able to further 565 
investigate whether the complex was reductant-sensitive. We are not aware of 566 
reports of similar F-box protein:Skp1 gel complexes (though such complexes are 567 
observed elsewhere (65, 66)), nor is it apparent to us that others in the field have 568 
looked directly for such a complex, or have been in a position to observe it. The 569 
cullin-1 that co-purified with TAP-tagged fpv014, however, does not appear to 570 
form a co-migrating complex with it on the immunoblot. Because the interaction 571 
of cullin-1 with F-box proteins is indirect, via Skp1, it is not perhaps not 572 
surprising that an fpv014:cullin-1 complex should be less stable than an 573 
fpv014:Skp1 complex. Although the cullin-1 that co-purified with TAP-tagged 574 
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fpv014 did not form a complex with the fpv014 on the immunoblot, it migrated 575 
more slowly than the cullin-1 in the control lysate. There is a precedent for this 576 
observation in that two similar size bands co-purified with GFP-tagged myxoma 577 
virus MNF protein. The predominant slower form immunoblotted with an 578 
unspecified anti-ubiquitin antibody (41). There is no indication at this stage 579 
whether fpv014 stabilised the modified form of cullin-1 in the cell, or whether it 580 
was solely (or predominantly) the modified form that co-purified with TAP-581 
tagged fpv014. We have not been able to investigate whether the cullin-1 that co-582 
purified with TAP-tagged fpv014 was ubiquitinated, but we are aware that the 583 
size difference observed between it and the cullin-1 from control lysates could 584 
equally correspond to the well-reported addition of the ubiquitin-like NEDD8 585 
adduct, rather than ubiquitin itself (67-69). 586 
 587 
Data shown here (Fig. 7 and unpublished) demonstrate that fpv014 does not 588 
inhibit transfected poly(I:C)-mediated induction of the ChIFN2 promoter. There 589 
are currently no clues as to the cellular target(s) of fpv014, and gaps in our 590 
understanding of the chicken type I IFN system render their identification even 591 
more complicated. Although the chicken system is largely equivalent to that of 592 
mammals, the as yet incomplete (and incompletely annotated) chicken genome 593 
sequence revealed significant differences between the mammalian and chicken 594 
systems. The absence of the RIG-I gene from the chicken, but not from all avian 595 
species (70), and the retention of mda-5 (71, 72) have already been reported and 596 
their possible implications considered. Other key components remain 597 
unaccounted for.  For instance, two major transcription factors implicated in 598 
type I IFN mRNA expression in mammals are constitutively expressed IRF-3 and 599 
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IFN-inducible IRF-7 (73), but in the chicken the gene encoding only one of them 600 
(ChIRF-3, NP_990703) is found, although it is actually most closely related to 601 
mammalian IRF-7. Genes encoding IRF-9 and STAT-2 have also not yet been 602 
identified in the chicken (S. Goodbourn and C. Ross, unpublished). The biological 603 
consequences of these differences remain unclear but they, combined with a 604 
relative dearth of reagents for the chicken system, are likely to complicate 605 
elucidation of the mode of action of the FWPV IFN modulators, as well as 606 
understanding the interaction of avian innate systems with avian pathogens, not 607 
least with important zoonotic agents such as avian influenza virus H5N1 and 608 
West Nile virus. However, this new avian virus IFN modulator, together with 609 
another (fpv012, which blocks dsRNA-mediated induction of the ChIFN2 610 
promoter) reported in an accompanying manuscript, will provide useful reagents 611 
for probing the specific nature of the avian innate defences. 612 
 613 
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FIGURES LEGENDS 902 
 903 
Figure 1. Sensitivity of viruses to recombinant ChIFN1. Plaque reduction 904 
assays were performed using CEF infected with Semliki Forest virus, FWPV FP9 905 
or vaccinia virus (VACV) VTN or MVA in the presence of recombinant ChIFN1. 906 
(A) Photograph of crystal violet-stained CEF showing titration of ChIFN1 907 
inhibition of FP9 and MVA plaque formation. (B) Graph showing plaque 908 
production as a function of ChIFN1 concentration. The dotted line indicates the 909 
50% reduction end-point. Plaque formation is expressed as a percentage of 910 
plaques formed in mock-treated wells (mean of n=3). Each point represents an 911 
individual well, except for FP9 where points are the mean (4 wells from 2 912 
independent experiments) ± 1 SD. Symbols: squares, FP9; circles, VACV VTN; 913 
closed triangles, MVA II/85; open triangles, SFV A7(74).  914 
915 
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Figure 2. Characterization of the FWPV chimeric MVA library. (A) 916 
Distribution on the FWPV FP9 genome of fragments inserted in the chimeric 917 
MVA library. The integrity of FWPV inserts was examined by PCR, using internal 918 
primers from the overlapping fragments with primers flanking the insertion site. 919 
Inserts that were shorter than expected were labeled as “unstable”. Where 920 
duplicate viruses containing a particular fragment were recovered, the fragment 921 
is classified here as a “Full-length insert” if at least one derived recombinant 922 
virus was of the anticipated size. Regions of the FP9 genome that were not 923 
present in the recombinant MVA library are highlighted as “uncloned genome”. 924 
To scale. (B) Expression of fpv191 by MVA chimeras MVA-f50a and MVA-f50c. 925 
Lysates of uninfected or infected CEF were subject to 10% SDS-PAGE then 926 
immunoblotted using primary monoclonal antibody DE9 (38) at  1 in 200  and 927 
secondary goat anti-mouse IgG (Sigma-Aldrich) at 1 in 25000. Lane 1: Uninfected 928 
CEF. Lane 2: FP9 infected CEF. Lane 3: MVA-LZ CEF. Lane 4: MVA-f50a infected 929 
CEF. Lane 5: MVA-f50b infected CEF. Lane 6: MVA-f50c infected CEF. Lane 7: 930 
MVA-fC2b infected CEF. Amount of cell lysate loaded is expressed relative to that 931 
for the FP9-infected lysate (lane 2).932 
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Figure 3. Screening FWPV chimeric MVA for enhanced resistance to ChIFN1. 933 
CEF were pre-treated in triplicate with ChIFN1 (10 U ml-1) or mock treated with 934 
DMEM 2% FBS, for 18 h. The medium was aspirated and cells were infected with 935 
chimeric viruses at 100 to 300 (A) or 50 to 200 (B) pfu/well. Virus was aspirated 936 
after 90 mins and semi-solid overlay was added. A second overlay containing X-937 
gal was added 3 days p.i. Plaque formation for each virus in ChIFN1-treated wells 938 
is expressed as the mean (n=3, ± SEM) percentage relative to mock-treated wells. 939 
Separate experiments are shown in (A) and (B). The screen shown in (A) used 940 
third bulk-passage, mycophenolic acid selected MVA-f3La (subsequently found 941 
to contain residual MVA-LZ) but that shown in (B) used fourth passage, plaque-942 
purified MVA-f3La (found to be free of parental MVA-LZ). 943 
 944 
945 
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Figure 4. qRT-PCR analysis of the expression of FWPV insert-specific genes 946 
by first and second stage FWPV chimeric MVA. Expression of mRNA specific 947 
for fpv012 and fpv014 in FP9- and control (MVA-fC2a) or FWPV chimeric MVA-948 
infected CEF was assayed by qRT-PCR, normalized against that for ChGAPDH. 949 
MVA-f3La is a first stage chimera carrying the FIR1 locus, MVA-F.012 and 950 
MVAF.014 are second round recombinants carrying only fpv012 and fpv014, 951 
respectively. Expression of mRNA specific for MVA A12L and the FWPV 952 
equivalent of A12L (fpv176) in FP9- and chimeric MVA-infected CEF, as vector-953 
specific controls, was assayed by qRT-PCR, normalized against that for 954 
ChGAPDH. (A) fpv012, open bars; (B) fpv014, chequered bars; (C) fpv176, 955 
horizontal hatched bars; (D) A12L; vertically hatched bars. Mean and standard 956 
deviation, at 8 and 16 hours post infection (hpi), are plotted from three 957 
independent experiments. Note differences in y-axis scales. 958 
 959 
 960 
 961 
962 
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Figure 5. Screening and characterization of second-round chimeric MVA to 963 
identify the FIR1 gene responsible for enhanced resistance to ChIFN1. CEF 964 
cells (in 9 cm2 dishes) were incubated with 1 ml DMEM 2% FBS (+ or – ChIFN1 at 965 
27 (A), 13 (B) or 6 (C) U ml-1) for 18 h. The medium was aspirated and cells were 966 
infected at 90 to 180 pfu/well. All viruses except control MVA-fC2a were plaque-967 
purified. MVA-f3La is a first stage chimera carrying the FIR1 locus; MVA-F.012, 968 
MVA-F.013 and MVAF.014 are second round recombinants carrying only fpv012, 969 
fpv013 and fpv014, respectively. Except in (A), which is an example of several 970 
experiments, the numbers of plaques formed in the ChIFN1-treated wells were 971 
expressed as a percentage of the mean (n=3) number of plaques formed in mock-972 
treated wells. (D) Plaque reduction assays were performed on FWPV chimeric 973 
MVA at a range of ChIFN concentrations from 5 to 200 U ml-1. IC50 values for 974 
ChIFN1 with each of the viruses were derived in PRISM (Graphpad) using non-975 
linear fits of the log converted ChIFN1 concentrations against percentage 976 
normalized plaque responses. IC50 values are plotted with 95% confidence 977 
intervals. Two-way ANOVA: * , p<0.05; **, p<0.01. 978 
 979 
980 
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Figure 6. Characterization of the expression of fpv014 in FWPV. (A) Analysis 981 
of the kinetics of expression of mRNA specific for fpv014 in wild-type FWPV was 982 
performed by qRT-PCR, using as controls FWPV genes fpv100 (ortholog of VACV 983 
E4L; RNA polymerase subunit RPO30) and fpv168 (ortholog of VACV A4L). 984 
Expression in the absence and presence of poxviral DNA replication inhibitor 985 
AraC was normalized against that for ChGAPDH. Mean and standard deviation 986 
are plotted from three independent experiments. (B) Expression of TAP-tagged 987 
fpv014, either full-length (FL) or C-terminally deleted (CtDel), inserted back into 988 
the native locus in FWPV FP9 under control of its cognate promoter, detected by 989 
immunoblotting of SDS polyacrylamide gels with anti-FLAG antibody (Sigma) 990 
and anti-mouse secondary antibody (LICOR) as per the manufacturers’ protocols. 991 
The immunoblots were imaged using a LICOR Odyssey. Samples were obtained 992 
24 hours post infection at an moi of 3. Molecular weight markers (M) are shown, 993 
as are the predicted masses of FL (53 kDa) and CtDel (50 kDa) TAP-tagged 994 
fpv014. 995 
996 
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Figure 7. Characterization of an fpv014 knockout mutant of FWPV.  (A) Like 997 
parental FWPV FP9, but unlike one defective in fpv012 (Del012), an FP9 mutant 998 
defective in fpv014 (Del014) retains full ability to block poly(I:C)-mediated 999 
induction of the ChIFN-2 promoter. Chicken DF1 cells were transfected with the 1000 
ChIFN-2 promoter reporter (pChIFN-2lucter) and the constitutive LacZ reporter 1001 
plasmid pJATlacZ. Following recovery for 24 hours, cells were either left 1002 
uninfected or infected with parental FWPV FP9 or single-gene mutants of FP9, at 1003 
an MOI of 10. Following infection for 4 hours, cells were either left untreated or 1004 
were transfected with poly(I:C) (10µg ml-1) and incubated for 16 hours. 1005 
Luciferase assays were carried out and data were normalised using β-1006 
galactosidase measurements. Each sample was compared to the uninfected, 1007 
poly(I:C)-treated control to calculate percent induction. Results show the mean 1008 
(n=3) + SD. (B) Plaque reduction assays were performed on parental and fpv014 1009 
knockout (Del014) FWPV FP9 at a range of ChIFN1 concentrations from 1 to 1010 
10000 U ml-1. IC50 values for ChIFN1 with each of the viruses were derived in 1011 
PRISM (Graphpad) using non-linear fits of the log converted ChIFN1 1012 
concentrations against percentage normalized plaque responses. IC50 values are 1013 
plotted with 95% confidence intervals. 1014 
1015 
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Figure 8. fpv014 is an ANK/PRANC protein that associates with Skp1 and 1016 
cullin-1. 1017 
(A) Domain structure of fpv014 showing N-terminal ankyrin (ANK) repeats as 1018 
well as the C-terminal F-box motif and the larger, encompassing PRANC domain. 1019 
To scale. (B) Chicken cullin-1 amino acid sequence (XP_418878) aligned (dots 1020 
indicate identical residues) with that of human cullin-1 (NP_003583), showing 1021 
peptides (underlined) identified by mass spectrometric sequence analysis of 1022 
proteins co-purified with TAP-tagged fpv014. (C) Immunoblot detection of Skp1 1023 
and cullin-1 co-affinity purified with TAP-tagged fpv014. DF1 control cell lysate 1024 
(‘Control lysate’) or final eluate of TAP-affinity purified lysate from a DF-1 cell 1025 
line inducibly expressing TAP-tagged fpv014 (“TAP-affinity-purified eluate”) 1026 
were subject to non-reducing 15% SDS PAGE then immunoblotted using mouse 1027 
anti-FLAG (Sigma Aldrich), mouse anti-Skp1 or mouse anti-cullin-1 (BD 1028 
Transduction Laboratories) at 1 in 1000 followed by goat anti-mouse IgG 1029 
(Sigma) at 1 in 25000. Molecular weight markers (M) are shown, as are the 1030 
predicted masses of TAP-tagged fpv014 (53 kDa), ChSkp1 (1 kDa) and ChCullin-1 1031 
(90 kDa). 1032 
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Anti-FLAG Anti-cullin-1Anti-Skp1
C
90 kDa >
